Presence of protein marks toxicity in leukemia
the ONA take:
A recent study examined the protein inositol polyphosphate 4-phosphatase II (INPP4B) in patients that had been diagnosed with acute myeloid leukemia.
When examined, the data indicated that the presence of this protein indicates a likely toxicity effect associated with chemotherapy.
Chemotherapy is a standard clinic treatment for this disease, but patients can now be screened for inositol polyphosphate 4-phosphatase II and recommended for other treatments less likely to be toxic as needed.
The researchers hope to explore exactly how the protein behaves in cancer cells, specifically related to chemoresistance, so the protein and pathway may one day be effectively targeted.
This research was led by PhD student Sewa Rijal from the Faculty of Medicine, Nursing and Health Sciences (FMNHS), under the supervision of Professor Andrew Wei and Professor Christina Mitchell, Dean of FMNHS. Findings were published in the journal Blood.
Presence of this protein indicates a likely toxicity effect associated with chemotherapy.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|